Kamada Ltd (KMDA) Stock Price, Quote & News

Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophyla...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 8 940 6472

Fax: 972 8 940 6473

Website: www.kamada.com

Address:

2 Holzman Street, Science Park PO Box 4081, Rehovot, Israel

Estimize Feb. 25 at 11:00 AM

Wall St is expecting 0.11 EPS for $KMDA Q1 [Reporting 05/26 BMO] http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_co

0 · Reply

OfficialStocktwitsUser Feb. 25 at 4:41 AM

$KMDA RSI: 71.67, MACD: 0.2892 Vol: 0.33, MA20: 8.53, MA50: 7.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

dup007 Feb. 24 at 3:13 PM

$KMDA KMDA broke 52W/H Excellent!

0 · Reply

dup007 Feb. 23 at 4:31 AM

$KMDA Kamada Ltd. (KMDA) Stock Analysis: Exploring a 50% Upside Potential https://www.directorstalkinterviews.com/kamada-ltd-kmda-stock-analysis-exploring-a-50-upside-potential/4121240897

0 · Reply

PortfolioVirtuoso Feb. 20 at 1:40 PM

$KMDA Kamada develops plasma-derived therapies. Revenue growth depends on commercialization. Pipeline progress adds optionality.

0 · Reply

MarthaMitchell302 Feb. 11 at 4:18 PM

$KMDA Kamada; plasma-derived biotech; commercial-stage, niche; growth via acquisitions and pipeline; royalty-based.

0 · Reply

BillionerOfKing Jan. 16 at 5:59 AM

$KMDA Current Stock Price: $8.21 Contracts to trade: $7.5 KMDA Jan 16 2026 Call Entry: $0.81 Exit: $1.12 ROI: 39% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

justpassingthrough_ Jan. 7 at 11:59 PM

$KMDA The kind of setup I personally love. Recently hit profitability, low debt, and strong guidance. This is a 100-150k buy for me. Buying tomorrow.

0 · Reply

Randall_Glover_31 Jan. 7 at 2:15 PM

$KMDA If you’re hunting “rerate setups”, this is what it looks like Regulatory wins in the UK + Switzerland, first Swiss footprint via Goldach partner, payer rail with 15+ insurers, Germany distribution via DoctorBox, and US clinical scale at ~2,000 with 2026 pivotal positioning Too many boxes checked for a true sleeper

0 · Reply

Sidoti Jan. 7 at 1:56 PM

New research today on @kamada $KMDA #sidotiresearch Read note: https://portal.sidoti.com/company-details/1000473/Kamada%20Ltd./1000489/CSR #investing #smallcap #microcap

0 · Reply

Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers

2026-01-07T17:55:49.000Z - 6 weeks ago

Kamada (KMDA) Projects Strong Revenue and EBITDA Growth by 2026

2026-01-07T16:49:38.000Z - 6 weeks ago

Kamada forecasts double-digit profitable growth in 2026

Thu, 18 Dec 2025 07:00:00 -0500 - 2 months ago

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

2025-12-08T19:00:14.000Z - 2 months ago

Kamada Ltd Corporate Update Call Transcript

2025-12-08T16:05:09.000Z - 2 months ago

Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook

Mon, 08 Dec 2025 11:05:09 -0500 - 2 months ago

Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook

2025-12-08T14:26:49.000Z - 2 months ago

Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript

2025-12-08T12:32:20.000Z - 2 months ago

Kamada (KMDA) Halts Phase 3 Trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency

2025-11-11T17:45:03.000Z - 3 months ago

Kamada (KMDA) is an Incredible Growth Stock: 3 Reasons Why

2025-11-10T21:00:45.000Z - 3 months ago

Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements

2025-11-10T19:06:51.000Z - 3 months ago

Q3 2025 Kamada Ltd Earnings Call Transcript

2025-11-10T15:51:37.000Z - 3 months ago

Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript

2025-11-10T14:30:04.000Z - 3 months ago

Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

2025-11-10T14:13:11.000Z - 3 months ago

Kamada (KMDA) Q3 2025 Earnings Call Transcript

2025-11-10T13:15:03.000Z - 3 months ago

Kamada (KMDA) Misses Q3 Earnings Estimates

2025-11-10T12:29:03.000Z - 3 months ago

Kamada (KMDA) Confirms 2025 Financial Outlook with Strong Growth Expectations

2025-11-10T12:17:39.000Z - 3 months ago

Kamada GAAP EPS of $0.09 in-line, revenue of $47M misses by $0.22M; reaffirms FY outlook

Mon, 10 Nov 2025 07:00:00 -0500 - 3 months ago

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

2025-11-10T11:12:02.000Z - 3 months ago

Earnings Scheduled For November 10, 2025

2025-11-07T18:03:37.000Z - 3 months ago

An Overview of Kamada's Earnings

2025-11-07T17:27:17.000Z - 3 months ago

Kamada Q3 2025 Earnings Preview

2025-11-07T12:21:06.000Z - 3 months ago

Earnings To Watch: Kamada Ltd (KMDA) Reports Q3 2025 Result

2025-11-06T14:15:03.000Z - 3 months ago

Countdown to Kamada (KMDA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

2025-11-05T14:40:04.000Z - 3 months ago

Should Value Investors Buy Kamada (KMDA) Stock?

2025-11-04T13:33:38.000Z - 4 months ago

Kamada (KMDA) Begins Study on CYTOGAM for Transplant Patients

Mon, 03 Nov 2025 07:00:00 -0500 - 4 months ago

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

2025-10-30T13:55:02.000Z - 4 months ago

Wall Street Analysts Believe Kamada (KMDA) Could Rally 113.15%: Here's is How to Trade

2025-10-22T16:45:01.000Z - 4 months ago

3 Reasons Why Growth Investors Shouldn't Overlook Kamada (KMDA)

Mon, 06 Oct 2025 13:29:00 -0400 - 5 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

2025-10-06T16:45:03.000Z - 5 months ago

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

Wed, 27 Aug 2025 14:28:58 -0400 - 6 months ago

Kamada: Earnings Expansion Cycle With Embedded Margin Of Safety

2025-08-13T19:53:36.000Z - 6 months ago

Kamada Ltd. (KMDA) Q2 2025 Earnings Call Transcript

2025-08-13T08:32:30.000Z - 7 months ago

Earnings Scheduled For August 13, 2025

2025-08-12T16:37:49.000Z - 7 months ago

Kamada Q2 2025 Earnings Preview

2025-08-12T16:01:28.000Z - 7 months ago

An Overview of Kamada's Earnings

Wed, 06 Aug 2025 07:00:00 -0400 - 7 months ago

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025

2025-06-17T11:08:46.000Z - 9 months ago

Kamada confirms continuous business operations despite recent events in Middle East

Tue, 17 Jun 2025 07:00:00 -0400 - 9 months ago

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East

2025-06-10T12:13:43.000Z - 9 months ago

Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion

2025-05-14T17:48:01.000Z - 10 months ago

Kamada Ltd. (KMDA) Q1 2025 Earnings Call Transcript

2025-05-14T11:09:25.000Z - 10 months ago

Kamada beats top-line estimates; reaffirms FY25 outlook

Wed, 14 May 2025 07:00:00 -0400 - 10 months ago

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

2025-05-14T08:32:23.000Z - 10 months ago

Earnings Scheduled For May 14, 2025

2025-05-13T19:28:23.000Z - 10 months ago

Kamada Q1 2025 Earnings Preview

2025-05-13T19:01:01.000Z - 10 months ago

Earnings Preview For Kamada

Wed, 19 Mar 2025 07:00:00 -0400 - 1 year ago

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

2025-03-13T12:09:48.000Z - 1 year ago

Kamada Announces Dividend After Record-Breaking Year, Anticipates Further Double-Digit Growth

2025-03-05T16:06:43.000Z - 1 year ago

Kamada Ltd. (KMDA) Q4 2024 Earnings Call Transcript

2025-03-05T12:30:23.000Z - 1 year ago

Kamada declares $0.20 dividend

Mar 5, 2025, 7:05 AM EST - 1 year ago

Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth

Feb 26, 2025, 7:00 AM EST - 1 year ago

Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025

Jan 22, 2025, 7:00 AM EST - 1 year ago

Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America

Nov 13, 2024, 9:54 AM EST - 1 year ago

Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston

Aug 14, 2024, 1:45 PM EDT - 1 year ago

Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024

May 8, 2024, 11:55 AM EDT - 1 year ago

Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance

May 1, 2024, 7:00 AM EDT - 1 year ago

Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Mar 6, 2024, 2:22 PM EST - 2 years ago

Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:05 AM EST - 2 years ago

Kamada Issues 2024 CEO Letter to Shareholders

Mar 6, 2024, 7:00 AM EST - 2 years ago

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

Feb 28, 2024, 7:00 AM EST - 2 years ago

Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024

Dec 8, 2023, 6:42 PM EST - 2 years ago

Kamada: Kedrion Deal Locks In Growth

Dec 7, 2023, 11:00 AM EST - 2 years ago

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

Dec 6, 2023, 7:00 AM EST - 2 years ago

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

Dec 5, 2023, 12:00 PM EST - 2 years ago

Celebrating Seeking Alpha's New Analysts - November 2023 Edition

AGNC CROX DPZ FHI GRPN GRVY GTN

Nov 21, 2023, 10:11 AM EST - 2 years ago

Kamada: Solid Specialty Plasma Play

Nov 13, 2023, 11:08 AM EST - 2 years ago

Kamada Ltd. (KMDA) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 2 years ago

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Nov 8, 2023, 7:00 AM EST - 2 years ago

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

Oct 10, 2023, 7:37 AM EDT - 2 years ago

Kamada Provides Corporate Update on its Israel Operations

Oct 9, 2023, 8:53 AM EDT - 2 years ago

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

CGEN PLX TARO TEVA

Aug 30, 2023, 7:00 AM EDT - 2 years ago

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

Aug 16, 2023, 3:53 PM EDT - 2 years ago

Kamada Ltd. (KMDA) Q2 2023 Earnings Call Transcript

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Aug 9, 2023, 7:00 AM EDT - 2 years ago

Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.

Jun 21, 2023, 5:10 AM EDT - 2 years ago

Kamada: Deep Dive Following FIMI Placement, Rate Buy

May 24, 2023, 1:21 PM EDT - 2 years ago

Kamada Ltd. (KMDA) Q1 2023 Earnings Call Transcript

May 24, 2023, 7:10 AM EDT - 3 years ago

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

May 24, 2023, 7:05 AM EDT - 3 years ago

Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

May 24, 2023, 7:00 AM EDT - 3 years ago

Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds

May 17, 2023, 7:00 AM EDT - 3 years ago

Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023

Estimize Feb. 25 at 11:00 AM

Wall St is expecting 0.11 EPS for $KMDA Q1 [Reporting 05/26 BMO] http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_co

0 · Reply

OfficialStocktwitsUser Feb. 25 at 4:41 AM

0 · Reply

dup007 Feb. 24 at 3:13 PM

$KMDA KMDA broke 52W/H Excellent!

0 · Reply

dup007 Feb. 23 at 4:31 AM

$KMDA Kamada Ltd. (KMDA) Stock Analysis: Exploring a 50% Upside Potential https://www.directorstalkinterviews.com/kamada-ltd-kmda-stock-analysis-exploring-a-50-upside-potential/4121240897

0 · Reply

PortfolioVirtuoso Feb. 20 at 1:40 PM

$KMDA Kamada develops plasma-derived therapies. Revenue growth depends on commercialization. Pipeline progress adds optionality.

0 · Reply

MarthaMitchell302 Feb. 11 at 4:18 PM

$KMDA Kamada; plasma-derived biotech; commercial-stage, niche; growth via acquisitions and pipeline; royalty-based.

0 · Reply

BillionerOfKing Jan. 16 at 5:59 AM

0 · Reply

justpassingthrough_ Jan. 7 at 11:59 PM

$KMDA The kind of setup I personally love. Recently hit profitability, low debt, and strong guidance. This is a 100-150k buy for me. Buying tomorrow.

0 · Reply

Randall_Glover_31 Jan. 7 at 2:15 PM

0 · Reply

Sidoti Jan. 7 at 1:56 PM

New research today on @kamada $KMDA #sidotiresearch Read note: https://portal.sidoti.com/company-details/1000473/Kamada%20Ltd./1000489/CSR #investing #smallcap #microcap

0 · Reply

TapeAnalyst Dec. 25 at 3:16 PM

$KMDA The investment case increasingly rests on operational credibility rather than long‑range promises. Competitive differentiation needs clearer proof points. Momentum becomes sustainable only with dependable execution. Future re‑rating depends on turning narrative into measurable outcomes.

0 · Reply

SuperBusa Dec. 23 at 12:39 AM

$KMDA

0 · Reply

candlestickmaster Dec. 21 at 6:30 PM

I'm liking $KMDA long here.

0 · Reply

theflynews Dec. 18 at 5:06 PM

Midday Fly By: Micron reports Q1 beat, Trump Media to merge with TAE - $KMDA - https://thefly.com/permalinks/entry.php/KMDAid4259698?176607

0 · Reply

DARKP00L Dec. 18 at 12:11 PM

$KMDA 07:05 on Dec. 18 2025 Kamada Extends Canadian Blood Services Supply Tender By $10M-$14M For Four Plasma-Derived Products, Securing $5M-$7M Annual Sales Through Q1 2028 #tradeideas

0 · Reply

Estimize Dec. 18 at 11:00 AM

Wall St is expecting 0.08 EPS for $KMDA Q4 [Reporting 03/18 BMO] http://www.estimize.com/intro/kmda?chart=historical&metric_name=eps&utm_co

0 · Reply

SuperGreenToday Dec. 11 at 1:51 PM

$KMDA Share Price: $7.03 Contract Selected: May 15, 2026 $10 Calls Buy Zone: $0.50 – $0.62 Target Zone: $0.89 – $1.09 Potential Upside: 66% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TOOL88 Dec. 10 at 7:47 PM

$KMDA After almost a year of holding the stock, I sold it all today due to a lack of major catalysts and because of market makers who play with the price as they see fit. Good luck to those who stay.

0 · Reply

RunnerSignals Dec. 9 at 9:34 PM

Stock Upgrades Today $OCUL $KMDA $LEGN $BIOA $NBIX Biotech stars breaking out https://stocksrunner.com/news/2025-12-09-stock-upgrades-today-show-top-picks

0 · Reply

JarvisFlow Dec. 9 at 11:40 AM

HC Wainwright & Co. has updated their rating for Kamada ( $KMDA ) to Buy with a price target of 13.

0 · Reply

Market Cap	510.64M
Revenue (ttm)	160.95M
Net Income (ttm)	14.46M
EPS (ttm)	N/A
PE Ratio	24.44
Forward PE	18.72
Profit Margin	8.98%
Debt to Equity Ratio	0.04

Volume	145,400
Avg Vol	73,680
Day's Range	N/A - N/A
Shares Out	57.51M
Stochastic %K	93%
Beta	0.94
Analysts	Strong Sell
Price Target	$13.00